Search Results

Two-Year HORIZONS-AMI Data Published

April 26, 2011—George D. Dangas, MD, et al published findings from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial in Circulation (2011;123:1745–1756).

Final 3-Year Results Published for the SPIRIT Clinical Trials of Abbott Vascular's Xience V EES

September 18, 2013—George D. Dangas, MD, et al published the final 3-year results of the SPIRIT clinical trials program in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions (2013;6:914–922). The SPIRIT program is a clinical evaluation of the Xience V everolimus-eluting coronary stent system (EES; Abbott Vascular, Santa Clara, CA) for the treatment of patients with de novo native coronary artery lesions. This study sought to investigate whether the Xience V EES is superior to a paclitaxel-eluting stent (PES) with respect to long-term individual clinical outcomes.

BRAVO-3 Trial Shows Increased Risk of Early Stroke With New-Onset Atrial Fibrillation After TAVR

May 11, 2017—The Society for Cardiovascular Angiography and Interventions (SCAI) announced the presentation of data from the BRAVO-3 randomized trial showing that more than one-third of patients undergoing transcatheter aortic valve replacement (TAVR) had atrial fibrillation (AF) either at baseline or new-onset AF within 30 days after TAVR.

Studies Find Underrepresented Groups Remain at Highest Risk of Heart Attack Despite 50% National Incidence Decline

May 3, 2024—Two studies focusing on ST‐segment elevation myocardial infarction (STEMI) uncovered socioeconomic, race, and gender disparities that are associated with greater risk and less likelihood to receive certain procedures.

SCAI Expert Consensus Statement Addresses Management of Calcified Coronary Lesions Requiring Intervention

February 5, 2024—The Society for Cardiovascular Angiography & Interventions (SCAI) recently announced the publication of the “SCAI Expert Consensus Statement on the Management of Calcified Coronary Lesions.” According to the society, the statement outlines methods for interventional cardiologists to identify various types of calcified coronary lesions and presents an algorithm to help them guide the use of these various calcium modification strategies.

Sunil V. Rao, MD, Named 2022-2023 President of SCAI

May 24, 2022—Sunil V. Rao, MD, FSCAI was recently named the 2022-2023 President of the Society for Cardiovascular Angiography & Interventions (SCAI). His appointment was announced at SCAI’s 2022 Scientific Sessions held May 19-22 in Atlanta, Georgia.

SCAI Leadership Remarks on FDA Panel Meeting on RDN

August 24, 2023—The leadership of the Society for Cardiovascular Angiography & Interventions (SCAI) issued a statement regarding the FDA Circulatory System Devices Panel that convened on August 22 to 23 to review scientific evidence on two interventional renal denervation (RDN) devices aimed at reducing blood pressure in adult patients with uncontrolled hypertension (HTN) who may be inadequately responsive to, or intolerant to, antihypertensive medications.

ORBITA-2 Shows PCI Relieves Chest Pain and Improves Exercise Capacity

November 11, 2023—The American Heart Association (AHA) announced that findings from the ORBITA-2 trial provide the first robust data confirming that percutaneous coronary intervention (PCI) relieves stable chest pain and improves exercise capacity among patients taking little or no chest pain medication.